DZNep inhibits GVHD mediated by donor CD8⁺ T cells. (A-C) The diagram shows the experimental design (A). Lethally irradiated B6 recipients (10 Gy [1000 rad]) were transplanted with TCD BM (5 × 10⁶) derived from C3H.SW mice (n = 10; ●), or with TCD BM + CD44^loCD8⁺ T_N cells (5 × 10⁵). Eight doses of DZNep were injected subcutaneously to CD8⁺ T-cell recipients (DZNep; n = 22) from day 3 to day 17 after transplantation, with vehicle treatment as control (Control; n = 22). The survival and clinical signs were monitored over time (B). Tissues were collected between day 25 and day 35 after transplantation for histologic examination. The graphs (mean ± SD) show the histologic scores of GVHD in B6 recipients (C). (D-E) Eight doses of DZNep were injected subcutaneously to CD8⁺ T-cell recipients (DZNep; n = 10) from day 14 to day 28 after transplantation, with vehicle treatment as control (Control; n = 10). The survival and clinical signs were monitored over time (D). (E) Tissues were collected on day 14 (before DZNep treatment) and day 81 (after DZNep treatment) after transplantation, respectively, and graphs show the histologic score of GVHD (mean ± SD).